Structures of molecules in the preclinical/clinical pipeline and the prototype natural product.
(1) Solblidotin, (2) Tasidotin, (3) Dolastatin, (4) Salinosporamide A, (5) Bryostatin, (6) Plinabulin, (7) Phenylahistin, (8) Halimide, (9) Trabectedin, (10) Cyanosafracin B, (11) Eribulin mesylate, (12) Halichondrin B, (13) Tetronamycin, (14) Nigericin, (15) K41A, (16) Manzamine A, (17) Ircinal A, (18) Karlotoxin 2